Clinical trials: Intussusception
- Condition Intussusception
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Infections, Rotavirus
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.
To assess the long-term efficacy and safety of the subjects during the third year after priming with 2 doses of GSK Biologicals' oral live attenuated HRV vaccine (Rotarix) in the primary vaccination study (102247).
- Trial name
- NCT00420316
- Testing
- Rotarix (primary vaccination study)
- Where
- 15 sites in Finland
- Volunteers
- 1,613 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Rotavirus
Special Drug Use Investigation for ROTARIX®
This study aims to determine the incidence of intussusceptions (IS) (including suspected cases of intussusception) after vaccination with Oral Rotarix® under clinical practice, in Japan.
- Trial name
- NCT01636739
- Testing
- Oral Rotarix®, Data collection
- Volunteers
- 10,982 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Intussusception
Study to Assess the Incidence of Intussusception in Children < 2 Years of Age in Singapore
This prospective study aims to estimate the incidence of intussusception among children < 2 years old through hospital-based surveillance in Singapore.
- Trial name
- NCT01177839
- Testing
- Screening sheets
- Where
- 5 sites in Singapore
- Volunteers
- 178 people
- Sponsor
- GlaxoSmithKline
Intussusception
Study on the Incidence of Intussusception (IS) in Children Aged < 12 Months in Japan
This study aims to analyse baseline data on IS in order to monitor the possibility of increased risk of IS in children aged <12 months after introduction of the Rotarix vaccination in Japan.
- Trial name
- NCT01479491
- Testing
- Data collection
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Intussusception (IS), Rotavirus Vaccines
Intussusception Surveillance After Rotarix Introduction in Mexico
GSK Biologicals' rotavirus vaccine, Rotarix™ has been recommended for universal use targeting infants through the Expanded Program on Immunization (EPI) in Mexico.
- Trial name
- NCT00595205
- Testing
- Hospital log review.
- Where
- Mexico
- Volunteers
- 786 people
- Sponsor
- GlaxoSmithKline
Intussusception, LRTI-related Post Neonatal Deaths
Implementing Hospital-based Active Surveillance Procedures for Vaccine Safety Monitoring at IMSS Hospitals in Mexico
This is an epidemiology study designed to implement hospital-based active surveillance for intussusception (IS) in children <1 year of age and lower respiratory tract infection (LRTI)-related deaths among children between 29 days…
- Trial name
- NCT00436358
- Testing
- Not applicable: none
- Where
- Mexico
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline